Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
2021 |
| gptkbp:ATCCode |
gptkb:R03DX10
|
| gptkbp:brand |
Tezspire
|
| gptkbp:CASNumber |
1610762-09-5
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:contraindication |
hypersensitivity to tezepelumab
|
| gptkbp:developedBy |
gptkb:AstraZeneca
gptkb:Amgen |
| gptkbp:halfLife |
26 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tezepelumab
|
| gptkbp:indication |
severe asthma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG2 lambda
|
| gptkbp:mechanismOfAction |
TSLP inhibitor
|
| gptkbp:molecularWeight |
~146 kDa
|
| gptkbp:monitors |
gptkb:physician
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:prescribes |
patients aged 12 years and older
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
back pain
injection site reaction rash arthralgia pharyngitis |
| gptkbp:target |
TSLP
|
| gptkbp:UNII |
6QY1D9K2TI
|
| gptkbp:usedFor |
asthma
|
| gptkbp:bfsParent |
gptkb:NCT03887455
|
| gptkbp:bfsLayer |
7
|